Controversial ‘Pay-for-Delay’ Deals Are Dropping

The Federal Trade Commission has seen a drop in the the number of ‘pay-for-delay’ deals between branded and generic drug companies, however, actually settlements between the two have actually increased. Read more here. (Source: First Report Managed Care, 1/15/16)

You might also be interested in:

Azar Touts Drop in Health Premiums, Administration September 28, 2018
Federal Agencies Partner to Combat Drug Monopolies, High Costs August 7, 2018
FDA Guidance Could Ease Generics’ Regulatory Path June 2, 2018
Physician Pay Pushes 257K Annually; $425K for Specialist Pay May 27, 2018
Research Suggests Low-Cost Generics at High Risk of Shortages December 14, 2018
Proposed HTA Regulation Gets Warm Welcome from Trade Groups June 27, 2018
AAM President Holds Firm Stance Against Recent Trade Deals November 4, 2018